Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
about
EGFR/Met association regulates EGFR TKI resistance in breast cancerOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerMicroRNA-7: a promising new target in cancer therapyProgress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancerWhat a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathwayMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerMolecular pathology of lung cancer: key to personalized medicine.Mechanisms of drug resistance in kinases.Ceritinib in ALK-rearranged non-small-cell lung cancer.Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyRe-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired ResistanceInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaEGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cellsThe Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat ModelsMass spectrometry-based secretome analysis of non-small cell lung cancer cell lines.Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Rational design of non-resistant targeted cancer therapiesA comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway.Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNAMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapyGeneration of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[α]indene Derivative in Lung Cancer CellsErlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularMolecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibitionTargeting the EGFR signaling pathway in cancer therapy.Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.EGFR-mutated lung cancer: a paradigm of molecular oncology.Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.Dabrafenib and its potential for the treatment of metastatic melanoma.Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalitiesClinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation.
P2860
Q24338635-296FF02A-43FE-4066-93B7-7A411405DDE0Q26745427-38F4243F-B134-44CD-B24E-79EA84DA5535Q26777905-CBFEDA57-792B-4BDF-A0E5-3C851973E7FBQ26784298-E917DE15-16C3-46C5-B626-8B3FCA1BD5B8Q26825780-43B8FDF0-AE7D-4ECF-81CA-58B7ECD81CD1Q26828860-B2C5B53D-373C-4235-BB43-60D6DC90ECA0Q27680966-D9CAA8D4-A875-4F55-84FD-67821FD611B3Q27691299-B0302E79-5BB8-4996-B172-D0EBE054EDC0Q27692567-F0C2903F-2143-46F6-9D9F-672EE42E8398Q27852989-5D77B37D-16AB-4463-88BF-4AED186AFE94Q27853360-EC87EDC5-E05C-4B3D-BD88-6CFFE64EEB53Q28073335-87A79AFB-4F53-45B8-ABBF-96F5A6A4B1E8Q28083239-A1F441D8-E0AC-4F17-8117-D809BF082471Q28303718-CA28A799-2010-4ABC-BC9B-7C7B5C96C9A9Q28478401-30488209-501B-4A41-ADA5-5033C1BCF5FDQ28820734-B6EE5DD4-91DA-461E-896D-8869022EE4CFQ30313775-578B108A-6274-4252-92DD-1A0139D33A23Q30850656-EEEB251D-CEA2-4BE3-915E-49ACAD599C6EQ33594692-5230C017-B95D-45DD-B93A-19A7A35281D8Q33605906-A224B057-2A5D-4454-BA7F-F1CBBACBD208Q33621143-FE0BF218-840E-4555-9DAD-E72954EE2FA3Q33677872-DA9538EE-4D1C-4EC5-99CD-E76B3ED7467FQ33686369-D9DA38E9-D8DE-468D-BFF0-A61B45828449Q33726782-AE0EF4B2-C74F-410E-BFB6-D0614ACBC987Q33737740-C87EE544-3BE1-4392-BDFF-9C3BF8F36389Q33828409-30C8B55B-D3BE-46E8-9F04-2FCBC8912BD1Q33829488-E346635C-4DDB-43E7-99CC-D449FCC6E937Q33912340-04E698B4-2FE8-4A83-B109-913CA2A5BFE3Q33945734-5A728456-EA4C-4D67-AD45-2F18871DEB90Q34002791-03DBBDEB-1783-40C0-ADD8-1EA2C2DF96CEQ34159011-A10D92EF-9A1F-4EDA-8045-7F853F7EB14BQ34187898-4C6AEBF5-0EDB-491A-A95E-E5F5C9978F44Q34246558-66FEB502-85F5-4BA1-840E-E6DC3131C66AQ34404209-3C7DA2A9-C373-43A2-A123-A6E7A2B3DC7BQ34406334-3E08C77C-9782-4514-B6B3-578A85270A06Q34500155-F663C1A0-DA20-4C7B-9310-FF1A7615B12DQ34646614-D1BFEE4C-A922-400E-8D6C-483A84D1603DQ34773458-3C3A58A7-C09B-42F3-9ACE-7FC2F0927632Q35146927-85885D52-28A1-469E-9124-DD0CF532E113Q35180028-A16D70D9-72BB-40C5-9B7A-F8EB79CA585F
P2860
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acquired resistance to epiderm ...... rowth factor receptor pathway.
@en
Acquired resistance to epiderm ...... rowth factor receptor pathway.
@nl
type
label
Acquired resistance to epiderm ...... rowth factor receptor pathway.
@en
Acquired resistance to epiderm ...... rowth factor receptor pathway.
@nl
prefLabel
Acquired resistance to epiderm ...... rowth factor receptor pathway.
@en
Acquired resistance to epiderm ...... rowth factor receptor pathway.
@nl
P2860
P356
P1433
P1476
Acquired resistance to epiderm ...... growth factor receptor pathway
@en
P2093
Kim-Son H Nguyen
Susumu Kobayashi
P2860
P304
P356
10.3816/CLC.2009.N.039
P407
P577
2009-07-01T00:00:00Z